People · Operator
Named in public records as an officer, director or promoter · active 2011–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ALDEA Pharmaceuticals, Inc. | — | Biotechnology | Series A | $27.5M | $334.9M | 2011 |
| Envisia Therapeutics, Inc. | — | Biotechnology | Series A | $14.7M | $365.8M | 2016 |
William Yelle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Yelle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Walker | 1 | 17 |
| Wende Hutton | 1 | 16 |
| Stephen Bloch | 1 | 15 |
| Ed Mathers | 1 | 11 |
| Timothy Shannon | 1 | 9 |
| Adrienne Graves | 1 | 6 |
| Seth Rudnick | 1 | 5 |
| Howard Rosen | 1 | 5 |
| Neal Fowler | 1 | 4 |
| Gary Phillips | 1 | 4 |
| Eric Linsley | 1 | 4 |
| Wenjin Yang | 1 | 2 |
| Daria Mochly-Rosen | 1 | 1 |
| Richard Shames, M.D. | 1 | 1 |
| Evgeny Zaytsev | 1 | 1 |
| Vernon Jiang, Ph.D. | 1 | 1 |
| Ben Yerxa | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.